Physician profile
Robin M Schaffran
NPI 1790785822
$10,711.12
in general payments reported to CMS, 2019-2025
38 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 75% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $830 · 2021: $1,337 · 2022: $1,462 · 2023: $1,831 · 2024: $1,748 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,242 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,242.01 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,519.82 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,089.95 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $987.36 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Janssen Biotech, INC. | $930.55 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $715.30 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $591.53 | 2019-2025 | Winlevi |
| Lilly USA, LLC | $566.78 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $514.55 | 2020-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $338.53 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Leo Pharma INC. | $331.91 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $313.12 | 2019-2025 | |
| Incyte Corporation | $291.22 | 2021-2025 | Opzelura |
| Ucb, INC. | $259.54 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $227.16 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $200.75 | 2019-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $198.65 | 2019-2022 | |
| Epi Health, LLC | $143.12 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $142.70 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $139.37 | 2023-2024 | Vtama |
| Allergan, INC. | $136.54 | 2019-2022 | |
| Glenmark Therapeutics INC. | $132.00 | 2019 | |
| Celgene Corporation | $129.15 | 2019 | |
| Arcutis Biotherapeutics, INC. | $122.10 | 2023-2025 | Zoryve |
| Merz North America, INC. | $115.47 | 2019-2025 | |
| Journey Medical Corporation | $113.82 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $109.56 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $75.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.88 | 2024-2025 | Spevigo |
| Nabriva Therapeutics, Plc | $38.17 | 2020-2021 | |
| Mission Pharmacal Company | $29.73 | 2019-2021 | |
| Krystal Biotech INC | $29.49 | 2023 | Vyjuvek |
| Organon LLC | $28.57 | 2025 | Vtama |
| Genentech USA, INC. | $19.48 | 2019 | |
| Dermira, INC. | $19.27 | 2020 | |
| Sandoz INC. | $16.79 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $15.41 | 2020 | |
| Encore Dermatology INC. | $15.12 | 2019 | |
| Prugen, INC. Pharmaceuticals | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Schaffran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.